Nintedanib-话题@MedSci

#Nintedanib#

24篇内容 | 1064人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1361778, encodeId=1bb91361e78d2, content=<a href='/topic/show?id=131d12808f9' target=_blank style='color:#2F92EE;'>#Nintedanib#</a>, objectTitle=Lancet Oncol：Nintedanib+多西他赛二线治晚期NSCLC有效, objectType=article, longId=31711, objectId=182231e11f0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=182231e11f0, replyNumber=0, likeNumber=49, createdTime=2014-03-12, rootId=0, userName=xiongke010, userId=ce68183, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=182231e11f0, moduleTitle=Lancet Oncol：Nintedanib+多西他赛二线治晚期NSCLC有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=182231e11f0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361777, encodeId=84e51361e77f6, content=<a href='/topic/show?id=131d12808f9' target=_blank style='color:#2F92EE;'>#Nintedanib#</a>, objectTitle=勃林格殷格翰向EMA提交nintedanib上市许可申请, objectType=article, longId=25501, objectId=394e2550182, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=394e2550182, replyNumber=0, likeNumber=38, createdTime=2013-10-19, rootId=0, userName=xiongke010, userId=ce68183, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=394e2550182, moduleTitle=勃林格殷格翰向EMA提交nintedanib上市许可申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=394e2550182)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361776, encodeId=30fa1361e76fc, content=<a href='/topic/show?id=131d12808f9' target=_blank style='color:#2F92EE;'>#Nintedanib#</a>, objectTitle=BI向EMA提交肺癌药物Nintedanib的上市许可申请, objectType=article, longId=25482, objectId=615d254828b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=615d254828b, replyNumber=0, likeNumber=42, createdTime=2013-10-18, rootId=0, userName=xiongke010, userId=ce68183, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=615d254828b, moduleTitle=BI向EMA提交肺癌药物Nintedanib的上市许可申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=615d254828b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361775, encodeId=188e1361e752b, content=<a href='/topic/show?id=131d12808f9' target=_blank style='color:#2F92EE;'>#Nintedanib#</a>, objectTitle=ASCO 2013：一线治疗之Nintedanib对索拉非尼的头对头临床试验, objectType=article, longId=19772, objectId=3ba219e728b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3ba219e728b, replyNumber=0, likeNumber=54, createdTime=2013-06-08, rootId=0, userName=xiongke010, userId=ce68183, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3ba219e728b, moduleTitle=ASCO 2013：一线治疗之Nintedanib对索拉非尼的头对头临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3ba219e728b)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Nintedanib

2020-05-29

xiongke010 (审核中...)

前往app查看评论内容

#Nintedanib#

Lancet Oncol：Nintedanib+多西他赛二线治晚期NSCLC有效

2014-03-12

xiongke010 (审核中...)

前往app查看评论内容

#Nintedanib#

勃林格殷格翰向EMA提交nintedanib上市许可申请

2013-10-19

xiongke010 (审核中...)

前往app查看评论内容

#Nintedanib#

BI向EMA提交肺癌药物Nintedanib的上市许可申请

2013-10-18

xiongke010 (审核中...)

前往app查看评论内容

#Nintedanib#

ASCO 2013：一线治疗之Nintedanib对索拉非尼的头对头临床试验

2013-06-08

科室
- - 订阅+
  - 更多科室
工具
服务